Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.

• Tech Mahindra Expands ServiceNow Alliance for Enterprise AI
• Aditya Birla Capital Shares Jump 4% on Gold Loan Foray
• Crompton Greaves Shares Rise on FY29-31 Outlook
• Escorts Kubota to Invest Rs 2,000 Crore in New UP Plant
• Brigade Enterprises Shares Jump 6% on HealthEdge Lease Deal

The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.